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Background:  HIV/hepatitis  C  (HCV)  coinfection  is a  major  concern  in global  health  today.  Each pathogen
can  exacerbate  the effects  of  the  other  and  affect  treatment  outcomes.  Understanding  the within-host
dynamics  of these  coinfecting  pathogens  is crucial,  particularly  in  light  of new,  direct-acting  antiviral
agents  (DAAs)  for HCV  treatment  that  are  becoming  available.
Methods  and  ﬁndings:  In this  study,  we  construct  a within-host  mathematical  model  of  HCV/HIV  coin-
fection  by  adapting  a  previously  published  model  of  HCV  monoinfection  to include  an  immune  system
component  in infection  clearance.  We  explore  the  effect  of  HIV-coinfection  on  spontaneous  HCV  clearance
and sustained  virologic  response  (SVR)  by building  in  decreased  immune  function  with  increased  HIV
viral load.  Treatment  is  modeled  by modifying  HCV  burst-size,  and  we  use  clinically-relevant  parameter
estimates.
Our model  replicates  real-world  patient  outcomes;  it outputs  infected  and  uninfected  target  cell
counts,  and  HCV  viral  load  for  varying  treatment  and coinfection  scenarios.  Increased  HIV  viral  load
and  reduced  CD4+ count  correlate  with  decreased  spontaneous  clearance  and  SVR  chances.  Treatment
efﬁcacy/duration  combinations  resulting  in  SVR  are  calculated  for HIV-positive  and negative  patients,
and  crucially,  we  replicate  the  new  ﬁndings  that  highly  efﬁcacious  DAAs  reduce  treatment  differences
between  HIV-positive  and  negative  patients.  However,  we  also ﬁnd  that if  drug  efﬁcacy  decays  sufﬁciently
over  treatment  course,  SVR  differences  between  HIV-positive  and  negative  patients  reappear.
Conclusions:  Our  model  shows  theoretical  evidence  of  the  differing  outcomes  of HCV  infection  in  cases
where  the  immune  system  is compromised  by HIV.  Understanding  what controls  these  outcomes  is
especially  important  with  the  advent  of  efﬁcacious  but often  prohibitively  expensive  DAAs.  Using  a  model
to predict  patient  response  can lend  insight  into  optimal  treatment  design,  both  in  helping  to  identify
patients  who  might  respond  well  to treatment  and  in  helping  to identify  treatment  pathways  and  pitfalls.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction and background
HIV–HCV coinfection is a whole greater than the sum of its parts,
due to the potentiating effect each virus can have on the other. It
is an increasing concern in certain populations including people
who inject drugs (PWID) and men  who have sex with men  (MSM).
Understanding the within-host dynamics of coinfection is crucial
for designing treatment strategies that will avoid complications
such as hepatotoxicity and treatment failure, while minimizing the
∗ Corresponding author. Tel.: +1 347 429 0986.
E-mail address: rbirger@princeton.edu (R. Birger).
cost of treatment. There is a rich literature on monoinfection with
each pathogen (e.g. Ho et al., 1995; Neumann et al., 1998; Perelson,
1999; Dixit et al., 2004; Perelson et al., 2005; Biafore and D’Attellis,
2006; Reluga et al., 2009; Debroy et al., 2011) but to the best of
our knowledge, within-host HIV–HCV coinfection has not yet been
modeled.
HIV and HCV are both viral infections that can be blood-borne.
They are often transmitted together, especially among PWID (Alter,
2006; Vickerman et al., 2013). The infections can interact synergis-
tically: broadly, HIV causes deterioration of the immune system,
which can lead to poorer control and clearance rates of HCV as
well as reduced probability of treatment success (Kim and Chung,
2009), while HCV may  increase progression rates of HIV through
http://dx.doi.org/10.1016/j.epidem.2015.04.001
1755-4365/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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Fig. 1. Within-host HIV–HCV interactions. Dashed black arrows represent mechanisms of HIV–HCV interaction described in the literature. Solid blue arrows represent
population-biological effects taken into account in our model. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of
the  article.)
chronic immune activation or increased CD4 apoptosis (Gonzalez
et al., 2010). Treatment success for HCV is deﬁned as achieving
sustained virologic response (SVR), i.e. HCV RNA is undetectable
during treatment and for 6 months beyond treatment end (Feld
and Hoofnagle, 2005).
We  approach clinical implications of coinfection with a
dynamic-static mathematical model, based on a previously pub-
lished dynamical model of HCV monoinfection (Dahari et al., 2005;
Reluga et al., 2009; Debroy et al., 2011) to include an explicit ele-
ment of immune control. We  then perturb the system by adding
HIV infection as a static parameter, which erodes immune control
and thus changes the HCV dynamics. Lastly, we explore how this
loss of control impacts HCV treatment outcomes.
Understanding phenomena that may  impact treatment out-
comes is especially important with the advent of new direct-acting
antiviral agents (DAAs) such as Sofosbuvir that are becoming avail-
able for HCV treatment. These new drugs are highly efﬁcacious, but
still very expensive, so thoughtful treatment design and adminis-
tration is necessary (NatMed, 2014; Guedj et al., 2010; Ahlén et al.,
2013).
1.1. Immune/HCV interactions
The immune response to HCV is complex and involves both
innate and adaptive components. The adaptive response to HCV is
mostly T-cell dependent. Virus-speciﬁc CD4+ and CD8+ responses
have been detected during acute infection, and it is thought
that these cells may  clear virus by lysing infected cells or by
cytokine/chemokine-mediated effects (Kim and Chung, 2009).
HCV may  be responsible for immune dysregulation itself; some
studies indicate an inverse correlation between HCV viral load and
CD4+ count (Mohsen et al., 2002). HCV may  also downregulate
proliferation of T cells or increase apoptosis. Increased immune
activation in coinfected versus monoinfected patients has been
noted, which also may  speed HIV progression (Gonzalez et al.,
2009). A schematic summary of HIV–HCV interaction effects is
shown in Fig. 1.
1.1.1. Empirical evidence for effect of HIV infection on HCV
clearance and treatment response
Patients who  are able to clear HCV spontaneously have been
noted to mount intense multispeciﬁc CD4+ and CD8+ responses,
in particular with HCV-speciﬁc CD4+ Th1 responses (Roe and
Hall, 2008). Complementarily, some studies show that lower CD4+
counts are associated with reduced probability of clearing (Kim and
Chung, 2009). However, HCV can avoid these responses through
mutation and inhibition of dendritic cell activation and produc-
tion of Th1 cytokines. This can prevent cytotoxic lymphocyte
(CTL)-induced apoptosis of infected hepatocytes, which can in turn
increase viral production (Roe and Hall, 2008).
Some HIV-positive patients do clear HCV, but in much lower pro-
portions than HIV-negative individuals. The correlative evidence
for mechanism is mixed. Higher rates of chronic HCV are inversely
correlated with CD4+ count according to some studies reviewed by
Kim and Chung (2009). A study in chimpanzees showed reduced
endurance of HCV-speciﬁc CD8+ CTL response after depletion of
CD4+ cells before reinfection; viremia upon reinfection was persis-
tent despite the presence of functional CD8+ T-cells (Grakoui et al.,
2003). Other studies have found more general negative correla-
tion between HIV viral load and SVR (Thomas, 2006; Roe and Hall,
2008). The phenomenon of increased persistence of HCV among
HIV-positive patients is related to and accompanied by an increased
HCV viral load.
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A number of empirical studies show elevated HCV viral load
(0.1–1 logs higher) among HIV-positive as compared to HIV-
negative patients (Di Martino et al., 2001; Danta et al., 2008;
Mohsen et al., 2002; Roe and Hall, 2008). The cause is most likely
reduced immune response: coinfection is associated with lack of
critical CD4+ response to HCV (Danta et al., 2008; Harcourt et al.,
2006). Indeed, the study in chimpanzees mentioned above showed
that CD8+ T-cells had impaired control of viral replication with
insufﬁcient CD4+ help (Grakoui et al., 2003), and there is evidence
that broad CD4+ responses play a major role in HCV clearance
(Diepolder et al., 1995).
1.1.2. Role of HIV treatment
In clinical settings where HCV treatment is available, most
coinfected patients will have been treated with anti-retroviral ther-
apy (ART) for HIV prior to receiving treatment for HCV despite
some risks of hepatotoxicity from ART (Soriano et al., 2007; Taylor
et al., 2012). However, even when ART is successful and results
in achievement of virological suppression, CD4+ recovery is often
incomplete. Many studies have shown that CD4+ count at simi-
lar durations after ART initiation varies widely, and is correlated
with a range of patient characteristics such as nadir CD4+ count
(Kaufmann et al., 2003; McKinnon et al., 2010; Takuva et al., 2014)
(see Supplementary Fig. 1). Correspondingly, there is evidence that
even coinfected patients who are treated for HIV have a lower prob-
ability of clearing HCV (Schnuriger et al., 2009) or achieving SVR
(Laguno et al., 2004; Dore et al., 2007; Andreoni et al., 2012).
1.2. Previous models of HCV
Some of the ﬁrst within-host models of HCV aimed to cap-
ture the dynamics of infection by pairing a mathematical model
with patient data from a trial of varying doses of interferon (IFN)
treatment (Neumann et al., 1998; Perelson, 1999). The viral load
patterns upon treatment observed (i.e. rapid initial decline in viral
load followed by extended slow decline) were consistent with the
main mechanism of IFN treatment being reduction in production
of new virus by infected cells (burst size). Higher doses were more
effective, and lower diversity of quasi-species were associated with
better response to treatment.
Extensions to this model take into account complexities sur-
rounding treatment response, such as non-response, rebound in
viral load (relapse), or treatment with other therapies (Perelson
et al., 2005; Dixit et al., 2004).
1.2.1. Models of extended infection
The aforementioned models deal with acute HCV infection and
treatment dynamics over the course of several days or weeks. HCV
can be a long course infection, however, and models can capture
longer term dynamics as well.
The model created for this study is based on previous works
(Reluga et al., 2009; Debroy et al., 2011; Dahari et al., 2005) and
explores treatment dynamics past initial infection in detail. The
conditions for achievement of SVR can be inconsistent. For exam-
ple, the “End-of-Treatment” response, deﬁned as undetectable viral
load (below 2 logs) at the end of a 24 or 48 week course of treatment,
is necessary but not sufﬁcient for SVR. Debroy et al. (2011) analyze
medium- and long-term responses leading to either a viral endemic
equilibrium or a disease-free equilibrium to establish mathemati-
cal criteria for each state. Depending on the initial conditions and
biological parameter values, there exists a possibility of bistabil-
ity for some patients (i.e. they have the capacity to clear infection,
but only if treated adequately). The parameter values depend on
patient immunological characteristics, as well as viral characteris-
tics and interactions, which can vary by genotype (as explored by
Smith et al., 2010). Our model aims to extend the analysis of these
previous models in scenarios of HIV coinfection.
2. Methods
2.1. HCV monoinfection model
The model proposed in this study follows closely the above-
referenced model (Dahari et al., 2005; Reluga et al., 2009; Debroy
et al., 2011). Following a standard ODE model proposed in earlier
work (Perelson and Nelson, 1999), with some variations such as
inclusion of infected hepatocytes in density dependence, the basic
form of the equations (without the immune system component) is
as follows:
dT
dt
= s + r1T
(
1 − T + I
Tmax
)
− dT − ˇTV
dI
dt
= ˇTV + r2I
(
1 − T + I
Tmax
)
− ıI
dV
dt
= pI − cV
Here, T, I, and V are the state variables representing, respec-
tively, uninfected Target cells (hepatocytes), Infected hepatocytes,
and free HCV Virus, s is the recruitment rate for uninfected hepa-
tocytes, r1 is the reproduction rate of uninfected hepatocytes, Tmax
is the maximum number/carrying capacity of target cells, d is the
death rate of uninfected target cells,  ˇ is the mass-action infection
parameter, r2 is the reproduction rate of infected hepatocytes, ı
is the clearance rate of infected hepatocytes, p is the number of
virions an infected cell produces in its lifetime (which can also be
interpreted as burst size), and c is viral clearance rate. With this
model of HCV monoinfection as a basis, we can build a new model
of HCV that includes the role of the immune system – speciﬁcally,
CD4+ cells, denoted H in the model equations. Work by Grakoui et al.
(2003) and others has illuminated to some extent the role of CD4+
cells in HCV control, and activation of CD4+ cells by HCV has been
documented (Lechner et al., 2000; Bowen and Walker, 2005). The
model proposed here thus incorporates a dependence of the HCV
clearance rate on CD4+ count (˛) and a dependence of the activa-
tion rate of CD4+ cells on HCV infected cell count (). The equations
thus become
dT
dt
= s + r1T
(
1 − T + I
Tmax
)
− dT − ˇTV
dI
dt
= ˇTV + r2I
(
1 − T + I
Tmax
)
− ı(1 + ˛H)I
dV
dt
= pI − cV
dH
dt
= sH(1 + I)  − dHH
where sH is the recruitment rate of CD4+ cells, and dH their death
rate.
2.2. Immunological impact of HIV coinfection on HCV
Introducing HIV infection into the system will have an impact on
its dynamics. Rather than including the full complexity of within-
host HIV dynamics in this model, we have chosen to take advantage
of the differing time scales of asymptomatic HIV infection and HCV
treatment. Therefore, we  use HIV set-point viral load as a constant
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parameter (rather than a state variable with its own dynamics)
so it contributes as a mass-action depleter of the immune system
compartment. Perturbing the system by adding a component of
HIV-infection changes the stability dynamics. To maximize simplic-
ity in the model, HIV infection was therefore modeled as a single
viral load, denoted by VH, representing the set-point viral load. The
equation for H thus becomes
dH
dt
= sH(1 + I)  − dHH − ˇHVHH
where ˇH is the mass-action infection parameter for HIV. Due to
the static nature of the incorporation of HIV into this model, we
are unable to capture dynamically the process of immune recovery
after ART for HIV. However, as immune recovery is often incom-
plete, we can use lower values of H (we can vary sH to generate
these values when VH≈ 0) to simulate a depleted immune system
and thus capture the dynamics of HCV in HIV patients on ART.
2.3. HCV treatment
Treatment efﬁcacy was included in the model as a parameter ε
controlling viral production rate as in previous work (Neumann
et al., 1998), and following Snoeck et al. (2010) and Dixit et al.
(2004), we have implemented a cure boundary such that virus
stops being produced when infected cell count drops below 1. The
equations become
dT
dt
= s + r1T
(
1 − T + I
Tmax
)
− dT − ˇTV
dI
dt
= ˇTV + r2I
(
1 − T + I
Tmax
)
− ı(1 + ˛H)I
dV
dt
= (1 − ε)pI − cV
dH
dt
= sH(1 + I) − dHH − ˇHVHH
This formulation allows for implementation of imperfect treat-
ment for varying durations in this model. As explored in the next
section, these combinations can reveal the uncertainty surrounding
cure inherent in certain patients.
2.4. Bistability analysis
This model allows for cure in two types of patient systems.
As explored by Snoeck et al. (2010), including the cure bound-
ary allows the model to replicate viral dynamics in patients in
whom infection is effectively cleared (<1 infected hepatocyte in the
modeled population). These patients do not exhibit true bistability;
if infected hepatocytes are not completely cleared, the viral load
will bounce back even from undetectable levels. In some patients,
however, the system can by truly bistable and when infected cell
count drops below a certain non-zero level, the patient will achieve
SVR even if virus is not initially eradicated.
To explore the stability dynamics of the model, it can be useful
to make the quasi-steady state approximation. Because the viral
dynamics happen on a faster time scale than the cell dynamics, we
can simplify the equations as
dT
dt
= s + r1T
(
1 − T + I
Tmax
)
− dT − (1 − ε) ˜ˇTI
dI
dt
= (1 − ε) ˜ˇTI + r2I
(
1 − T + I
Tmax
)
− ı(1 + ˛H)I
dH
dt
= sH(1 + I)  − dHH − ˇHVHH
V = p
c
I
where ˜ˇ = (p/c)ˇ.
Following Debroy et al. (2011), we calculate the within-host R0
by setting dI/dt > 0 at the start of the infection (before treatment, so
the ε term disappears), when I ≈ 0:
dI
dt
= ˜ˇTI + r2I
(
1 − T + I
Tmax
)
− ı(1 + ˛H)I > 0
˜ˇT + r2
(
1 − T
Tmax
)
> ı(1 + ˛H)
R0 =
˜ˇT0 + r2(1 − (T0/Tmax))
ı(1 + ˛H0)
> 1
where T0, H0 are the initial values of uninfected hepatocytes and
activated CD4+ cells in the absence of infection.
T0 =
Tmax
2r1
(
(r1 − d) +
√
(r1 − d)2 + 4s
r1
Tmax
)
and
H0 =
sH
dH
Bistability of a viral endemic equilibrium (EE) and a disease-free
equilibrium (DFE) can occur under certain circumstances (Debroy
et al., 2011). In this monoinfection model, bistability occurs when
the within-host R0 is close to or less than 1, and r2 > ˜ˇTmax,
r2 > ı(1 + ˛H0). There is some evidence that HCV can increase the
reproduction rate of infected cells to replace cells that were tar-
geted successfully by immune response (Roe and Hall, 2008; Kim
and Chung, 2009; Block et al., 2003; Erhardt et al., 2002; Hu et al.,
2013), so stability of an endemic equilibrium given this condition
has some clinical basis. The role of r2 in the bistability in this system
has an intuitive basis as well: the infected cell growth rate receives
contributions both from infected replication and from virion infec-
tion of healthy cells. More basically, when r2 > r1, i.e. the maximum
proliferation rate of the infected cells is greater than the maximum
proliferation rate of infected cells, the infection can invade even
at a stable, disease-free equilibrium. Interestingly, HIV-coinfection
impacts greatly the stability of the DFE, but does not impact inva-
sion probability at the stable DFE. Derivation of these conditions
can be found in Appendix A.
The stability surrounding R0 divides patients into four types:
never achieving SVR (R0 > 1), always achieving SVR (R0 < RC where
RC is the critical bifurcation value), or in the bistable region, either
experiencing spontaneous cure or experiencing viremia but with
the ability to be pushed into the clearance area by treatment. With
this formulation, it is possible to analyze numerically which val-
ues of duration and efﬁcacy can push a patient from one basin of
attraction to the other (i.e. endemic equilibrium to clearance). SVR
is thus dependent on a combination of critical efﬁcacy and time.
When the immunological impact of HIV-coinfection is included,
however, the stability dynamics change, reducing the probability
of achieving SVR (Andreoni et al., 2012).
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Fig. 2. Model comparison with data. Panel a shows patient data redrawn from Snoeck et al. (2010), displaying the ﬁve types of long-term treatment outcome: SVR, null
response, partial response, breakthrough, and relapse. Panel b shows model scenarios from the model including free virus displaying these same ﬁve outcomes. Panel c shows
short-term treatment dynamics over the ﬁrst two weeks of treatment; model outputs are paired with data redrawn from Neumann et al. (1998). Panel d shows the same
scenarios as b, using a version of the model wherein the quasi-steady state assumption has been implemented, demonstrating that the long-term dynamics can be recovered.
Parameter values for each simulation are listed in Supplementary Table 3.
3. Results
The model can qualitatively replicate viral dynamics observed
in HCV patients after treatment and described in previous stud-
ies such as Neumann et al. (1998) and Snoeck et al. (2010). Fig. 2
demonstrates this replication, showing both the initial biphasic
decline (model outputs paired with data redrawn from Neumann
et al., 1998 in panel c), and longer-term dynamics paired with
data redrawn from Snoeck et al. (2010) (panels a and b). The
model outputs shown are not explicitly ﬁtted to the data presented,
but nonetheless replicate the viral trajectories. When the quasi-
steady state assumption is made, these longer-term dynamics can
be similarly qualitatively recovered, as seen in panel d of Fig. 2.
Using an example patient (Patient I) who exhibits true bistability
of endemic- and disease-free equilibria allows us to visualize the
impact of HIV infection. Simulating different levels of the deple-
tion in CD4 count that might occur during the asymptomatic phase
of HIV infection shows that the zone of bistability shrinks with
decreasing CD4+ count. The region of bistability is a region wherein
the within-host R0 is less than or close to 1 but greater than a cer-
tain critical reproductive number, RC (see Appendix for calculation
of RC). In this region, there are three distinct equilibria: the sta-
ble endemic equilibrium (EE), the disease-free equilibrium (DFE)
and a third, unstable EE. This unstable endemic equilibrium divides
viral load measures into two basins of attraction: toward the DFE
and toward the stable EE. Fig. 3 shows how this region of bista-
bility encroaches farther into the region of spontaneous clearance
the lower the CD4+ count, and eventually erases the possibility
of spontaneous clearance for realistic values of ı. The presence of
HIV depletes the immune system component (even after successful
treatment of HIV with ART) thus decreasing the probability of spon-
taneous clearance of HCV for this patient. The patient represented
has values for parameters drawn from the realistic distributions
described in Debroy et al. (2011) (and Supplementary Table 1). HIV
parameters are adapted from Biafore and D’Attellis (2006). The set-
point viral load values tested are derived from the estimates of the
variability of HIV set-point viral load by Fraser (2007). The coin-
fection inﬂuence parameters are theoretical estimates chosen such
that model reproduces viral load levels and relationships; while
much empirical work has demonstrated qualitative relationships
indicated by these parameters (e.g. Grakoui et al., 2003; Lechner
et al., 2000; Bowen and Walker, 2005), this work does not allow for
their precise determination in this context.
The bifurcation diagram demonstrates how spontaneous clear-
ance can become non-clearance in a patient for whom the
bistability criteria hold, but using this model we can also
demonstrate differential treatment responses. Fig. 4 shows two
sample patients who  are both able to achieve SVR in a non-
immunosuppressed state. Panel a shows Patient I, the same bistable
patient as in the bifurcation diagram. Panel b shows Patient II, who
does not demonstrate true bistability, but is able to achieve SVR
with the cure boundary (i.e. when the infected hepatocyte count
drops below 1). For both patients, when HCV-mononinfected, SVR
is achievable after 24 weeks of treatment at levels of ∼80% efﬁcacy.
However, for both patients, when CD4+ is depleted partially (as in
a state where HIV viral load is controlled but CD4+ count has not
fully recovered), 24 weeks of treatment is insufﬁcient and relapse
occurs: the patient must be treated for 48 weeks to achieve SVR. In
the case when each patient is profoundly immunosuppressed (as
in untreated HIV, or no immunologic response to treatment after
very low nadir CD4+ count), SVR cannot be achieved even with 48
weeks of treatment. This time series illustrates the sensitivity of
treatment prognosis to HIV status, as well as the phenomenon that
early treatment response is necessary but not sufﬁcient to predict
whether SVR will be achieved.
However, when treatment efﬁcacy is high enough, as it can be
with the new direct-acting drugs that have recently been approved
(Jacobson et al., 2013; Lawitz et al., 2013; Keating and Vaidya,
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Fig. 3. Bifurcation diagram of stable and unstable equilibrium HCV viral loads with varying CD4+ count. This ﬁgure shows the growing bistable region and corresponding
shrinking region of spontaneous clearance for a parameter set with varying ı and within-host R0. The x-axis represents the within-host R0 in the HIV-free scenario with
the  given clearance rate parameters. The y-axis represents equilibrium HCV viral load. To the left of the bifurcation points is the zone of spontaneous clearance. If viral load
can  be pushed below the dotted lines (unstable equilibria), with sufﬁcient treatment, the patient will then be in the region of stable DFE and will be able to achieve SVR.
ı  × (1 + ˛H) ranges from d to 3 for varying CD4+ counts*. The other parameters are as follows: s = 4365, Tmax = 4.016 × 106, d = 1.06 × 10−3, ˇc = 7.3 × 10−8, p = 13.48, c = 10.06,
r1 = 2.7, r2 = 7.52, sH = 9, ˇH = 4.1 × 10−6, dH = 9 ×10−3,  ˛ = 5 ×10−3,  = 2 × 10−8. *Note: For lower CD4+ counts/higher HIV viral loads, the tips of the bifurcation trees could not
be  reached with clinically realistic values of ı. This fact implies that there would be no realistic zone of spontaneous clearance for this patient when CD4+ count falls below
a  certain point, though SVR might still be possible with sufﬁcient treatment duration and efﬁcacy.
2014), HIV coinfection with incomplete CD4+ recovery no longer
compromises SVR chances to the same extent. Sofosbuvir has been
shown to effect SVR within 12–24 weeks in both HIV-positive
and HIV-negative HCV patients (Fernández-Montero et al., 2013;
Sulkowski et al., 2014a,b; Rodriguez-Torres et al., 2015), and our
model replicates this result for the above theoretical patients I
and II (Fig. 6, panels a and b), (we still predict treatment fail-
ure for short-duration treatment when the patients are severely
immunocompromised, but most trials of Sofosbuvir in coinfected
patients have been among patients on ART with stable CD4+, e.g.
Sulkowski et al., 2014a,b; Rodriguez-Torres et al., 2015). Fig. 5
shows the pairs of treatment efﬁcacies and durations that lead to
SVR for Patients I and II with and without depleted CD4+ count from
HIV coinfection. Each point on each line represents the minimum
treatment duration necessary to achieve SVR for the corresponding
treatment efﬁcacy. In each of these scenarios, the model was run
Fig. 4. Effect of depleted CD4+ on infection clearance. This ﬁgure shows HCV viral load trajectories for two  sample patients with different treatment efﬁcacies and durations
under  initial conditions of normal CD4+ count (∼1000 per L, HIV negative), and depleted CD4+ count (∼600 per L, suppressed HIV with incomplete immunologic recovery),
and  very low CD4+ count (∼10 per L, unsuppressed HIV) for treatment courses of 24 and 48 weeks. It can be seen that a treatment course of 24 weeks that is sufﬁcient to
achieve  SVR when the patient has a normal CD4+ count is no longer sufﬁcient for either HIV positive scenario, even when CD4+ count has partially recovered. However, when
treatment is extended to 48 weeks, the patients are able to achieve SVR when CD4+ count has partially recovered. Panel a shows these scenarios for Patient I, a theoretical
patient exhibiting classic bistability, while panel b shows Patient II, a theoretical patient who requires the cure boundary condition to achieve SVR.
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Fig. 5. Treatment and efﬁcacy combinations for (a) Patient I and (b) Patient II. Each point on each line denotes the minimum treatment duration necessary to achieve SVR for
the  corresponding efﬁcacy, for varying initial CD4+ counts. For any combination above a line, SVR is achieved, while for any combination below the line, SVR is not achieved.
All  scenarios were run for 96 weeks to assure that any potential relapse was captured.
Fig. 6. High-efﬁcacy treatment with short-term cure. Panels a and b demonstrate that high efﬁcacy treatment, as with DAAs, can result in SVR over a short duration (12–24
weeks)  for Patients I and II, respectively, even with incomplete CD4+ recovery (though when each patient is severely immunocompromised, short-term cure is still unlikely).
However, panels c and d show the same scenarios, but with treatment efﬁcacy declining from 95% to 70–75% efﬁcacy over the course of 12–16 weeks. When the CD4+ count
is  depleted or low (HIV-positive), the patients respond initially, but relapse after treatment efﬁcacy falls below a certain level.
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for 96 weeks (well past the maximum treatment duration tested) in
order to capture any relapse that might occur. This ﬁgure demon-
strates how the minimum acceptable treatment efﬁcacies and
durations depend strongly on HIV status. It can be seen in this ﬁgure
that duration/efﬁcacy pairs that will result in SVR for the patients
when they are HIV-negative fall in the “No SVR” region when the
patient has a depleted CD4+ count. As CD4+ drops, the minimum
treatment efﬁcacy necessary for SVR increases, as does minimum
duration for a given efﬁcacy in some cases. When the patients are
severely immunocompromised, only very high efﬁcacy treatment
will result in SVR. Lastly, as Fig. 5 suggests and Fig. 6 shows in pan-
els c and d, in the likely event that treatment efﬁcacy declines
over time due to non-adherence, drug resistance, or concentra-
tion decay, the differences between monoinfected and coinfected
patients may  reappear, wherein coinfected patients relapse after
treatment.
4. Discussion and conclusion
In this study, we propose a model of within-host HCV infec-
tion that is able to capture broadly the impact of concurrent
treated or untreated HIV infection on clearance and long-term
cure of HCV in coinfected patients. To the best of our knowl-
edge, it is the ﬁrst within-host model of HIV–HCV coinfection; it
builds on previous models of HCV monoinfection (Debroy et al.,
2011; Reluga et al., 2009) and HIV monoinfection (Biafore and
D’Attellis, 2006; Perelson and Nelson, 1999) and allows for an
explicit role of the immune system in HCV disease course. Our
model qualitatively replicates results of empirical research show-
ing that HIV-coinfected HCV patients have reduced probability of
spontaneous clearance of HCV as well as reduces rates of achieving
sustained virologic response (Kim and Chung, 2009; Mohsen et al.,
2002; Di Martino et al., 2001). Similarly, we replicate newer empiri-
cal ﬁndings indicating that highly efﬁcacious direct-acting antiviral
agents (DAAs) reduce treatment differences between HIV-positive
and HIV-negative HCV patients (Fernández-Montero et al., 2013).
This study adds to the literature a way of capturing HCV within-
host dynamics while accounting for the role of the immune system
under conditions of HIV infection. It contains the ﬂexibility and
tractability necessary for testing hypotheses about clearance and
treatment. We  provide a framework which may  be useful for
assessing a patient’s chance of responding to treatment, given
certain virologic, immunologic and therapeutic parameters. Our
choice to model HIV statically allows our model capture how
an immunocompromised patient can respond differently to HCV
infection and subsequent treatment, while avoiding the problem
of parameter proliferation.
There are several limitations of the model related to the com-
plexity of the system. First, the bistability criterion that the
proliferation rate of infected cells must be greater than the pro-
liferation rate of uninfected cells only has partial support in the
literature. Some studies report that HCV core protein can induce
proliferation in hepatocytes (Erhardt et al., 2002; Hu et al., 2013;
Kim and Chung, 2009; Roe and Hall, 2008) and inhibit immune-
mediate cell killing (Block et al., 2003), while others report slowed
proliferation in HCV-infected cells (Kannan et al., 2011). However,
there are may  be other mechanism of bistability, such as inter-
feron refractoriness of some cells as proposed by Padmanabhan
et al. (2014) that would yield similar impacts under the HIV coinfec-
tion conditions proposed in this model. Second, the model assumes
very simpliﬁed within-host HIV dynamics by only including HIV
viral load as a static parameter, so may  miss some of the sub-
tleties of CD4 decay and viral load changes through the course
of infection. However, this simpliﬁcation is appropriate for the
shorter relative time-courses of the HCV dynamics explored here.
Similarly, while we cannot model the explicit dynamics of treat-
ment of HIV with ART, we are able to manually replicate them
by using lower equilibrium values of CD4+ count. Third, the way
we model HCV treatment does not take into account pharmacoki-
netic/pharmacodynamic complexities beyond simple, exponential
decay of treatment efﬁcacy over time, but it is useful for making
baseline calculations. It has been used in the past for modeling
interferon (IFN) treatment (Debroy et al., 2011; Reluga et al., 2009;
Perelson, 1999), but may  in fact be a better representation of the
mechanisms of DAAs (Guedj et al., 2010). IFN works by creating an
antiviral environment inside susceptible cells, thereby decreasing
their chances of getting infected (Feld and Hoofnagle, 2005), while
ribavirin can act as a mutagen and cause some proportion of viri-
ons to be non-infectious (Dixit et al., 2004). Empirical evidence
suggests that response is not directly dependent on concentra-
tion over time, but maximum drug effectiveness is correlated with
treatment response. DAAs, however, mainly work to inhibit HCV
replication thereby having a more direct effect on viral burst-size
and infectiousness (Ahlén et al., 2013).
DAAs offer very promising prognoses for HCV patients, but
are still prohibitively expensive for many (Mehta and Asch, 2014;
NatMed, 2014). It is therefore crucial to assure that the drugs
are being administered properly. Using a model to predict patient
response may  lend insight into pre-treatment estimation of treat-
ment success, and could be helpful in monitoring effectiveness of
therapy over the course of treatment. For example, if a patient
requires or takes drug holidays, a model of this type may be helpful
in predicting the maximum drug holiday allowable without com-
promising treatment. As Fig. 6 shows, HIV has the potential to alter
treatment dynamics even in optimistic scenarios, underscoring fur-
ther the importance of understanding this system.
The model results presented here give a theoretical demonstra-
tion of the effect that HIV coinfection can have on the course of
HCV infection. While the system of HCV-HIV coinfection has many
layers of complexity, we are able to use a model with relatively
simple assumptions about pathogen and immune system inter-
action to qualitatively describe patient outcomes. Not only is an
HIV-positive patient less likely to clear HCV spontaneously, but also
less likely to respond to HCV treatment when treatment efﬁcacy is
below a certain level (Kim and Chung, 2009; Mohsen et al., 2002;
Di Martino et al., 2001). Understanding what drives these treat-
ment differences can help spare difﬁcult treatment and side effects
for patients who  are unlikely to respond to treatment, as well as
informing strategies to maximize treatment adherence. HIV-HCV
coinfection is a growing issue not just among injecting drug users,
but also among HIV-positive Men  who  have sex with Men  (MSM)
who may  experience both increased transmissibility of HCV due to
higher viral load and also increased susceptibility to sexually trans-
mitted HCV due to incomplete restoration of mucosal immunity
(Kim and Chung, 2009). It is thus vital to understand the within-host
dynamics of these coinfecting pathogens in order to better assess
treatment strategies and preempt shortfall and potential resistance
acquisition.
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